Intraretinal, subretinal fluid important biomarkers for BVCA outcomes in nAMD

Posted on

Intraretinal fluid (IRF) and subretinal fluid (SRF) are important biomarkers for predicting best-corrected visual acuity (BCVA) outcomes in patients with treatment-naïve neovascular age-related macular degeneration (nAMD) in routine clinical practice, according to a study.

In this retrospective, nonrandomized cohort study of 286-patient with nAMD, the mean BCVA was as follows:
-At baseline: 60.24 ± 18.63 37 Early Treatment Diabetic Retinopathy Study (ETDRS) letters
-At 6-months: 65.57 ± 16.56 ETDRS letters
-At 12- months: and 65.61 ± 17.37 ETDRS letters

The regression coefficient in the linear mixed-effects regression model quantifying the association between eyes in the fourth and first quartile of IRF and 12-month BCVA was -4.14 ETDRS letters; for SRF and 12-month BCVA it was -0.7 ETDRS letters.

IIyer AI, Muste JC, Kalur A, et al. Impact of Persistent Retinal Fluid in Patients with Neovascular Age-Related Macular Degeneration in Routine Clinical Practice. Ophthalmic Surg Lasers Imaging Retina. 2022; 53(6):317-324.